ICON Public Limited Company (ICLR)

ICON Public Limited Company is trading at $169.04, down 0.24% on the session. The 50 day average sits at $162.18 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 48.5, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $162.83 with resistance near $173.23, so that band frames the current range. Average daily movement is roughly $7.39, or about 4.4% of the share price, which is what any stop placement has to allow for. The overall health score of 56 out of 100 combines a trend score of 75, momentum of 39 and a risk score of 50.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.